Compiled 2026-09-26Data through 2026-04-242 min read
Dated source-based research · No live market data

Research summary

A research framework for 16 covered healthcare issuers, with explicit attention to financial comparability.

Industry context

Drug developers, device manufacturers and care providers depend on distinct clinical, reimbursement and operating economics.

Covered sample

LLY, JNJ, ABBV, MRK, NVS, AZN, AMGN, GILD, ABT, PFE, ISRG, VRTX, BMY, MDT, SYK, HCA. Selection favors available recent annual USD disclosures; it is not a market-cap ranking.

Financial evidence

The related sector data notes provide company-level observations for revenue growth, profitability, cash conversion and balance-sheet structure. They show the exact sample and period for every calculation.

Valuation context

Sector medians are descriptive reference points. Different business mixes, fiscal calendars and accounting choices prevent a single sector multiple from establishing fair value.

Risks and uncertainties

Patent expiry, trial outcomes, reimbursement changes, litigation and acquisition integration.

What to monitor

Product concentration, research investment, utilization, reimbursement and cash generation.

Sources & dates